List of Excipients in Branded Drug KETEK

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	KETEK	telithromycin	54868-5171	CELLULOSE, MICROCRYSTALLINE
Physicians Total Care Inc	KETEK	telithromycin	54868-5171	CROSCARMELLOSE SODIUM
Physicians Total Care Inc	KETEK	telithromycin	54868-5171	FERRIC OXIDE RED
Physicians Total Care Inc	KETEK	telithromycin	54868-5171	FERRIC OXIDE YELLOW
Physicians Total Care Inc	KETEK	telithromycin	54868-5171	HYPROMELLOSES
Physicians Total Care Inc	KETEK	telithromycin	54868-5171	MAGNESIUM STEARATE

KETEK Telithromycin Excipient Strategy and Commercial Opportunities

Last updated: September 8, 2026

KETEK, the brand name for telithromycin, has limited commercial value as a conventional oral antibiotic because of severe hepatotoxicity concerns, restricted regulatory status, discontinued U.S. marketing, and intense generic competition in the ketolide and macrolide classes. The most credible excipient opportunities are low-cost generic tablet manufacturing, supply-chain substitution, and formulation support for non-U.S. markets where telithromycin remains authorized. New dosage-form development has weak commercial logic unless it materially reduces hepatic exposure or addresses a defined regulatory need.

What is KETEK and what is its current regulatory status?

KETEK contains telithromycin, a semisynthetic ketolide antibiotic related to the macrolide class. It was developed for respiratory tract infections caused by susceptible bacterial pathogens, including community-acquired pneumonia.

The FDA approved KETEK in 2004 under New Drug Application 21-144. In 2006, the FDA required major labeling changes after reports of serious liver injury, including acute liver failure and deaths. The revised U.S. label added a boxed warning and restricted the approved indication primarily to community-acquired pneumonia.

Sanofi later discontinued U.S. commercial marketing. The product no longer has a meaningful U.S. branded-market opportunity, and any potential U.S. generic opportunity would depend on regulatory listing status, commercial demand, and the ability to manufacture an approved equivalent.

Attribute	KETEK
Active ingredient	Telithromycin
Dosage form	Film-coated oral tablet
Strength	300 mg
Original sponsor	Aventis, later Sanofi
U.S. approval	2004
U.S. NDA	21-144
Main use	Community-acquired pneumonia
Key safety issue	Severe hepatotoxicity
U.S. commercial status	Sanofi U.S. marketing discontinued
Primary formulation opportunity	Generic or supply-chain replacement
Biologic or biosimilar exposure	None

The FDA’s safety action materially reduced the addressable market. The product also competes with established macrolides, fluoroquinolones, beta-lactams, and other antibiotics with broader prescribing familiarity.

What excipients are used in KETEK tablets?

The KETEK tablet uses conventional immediate-release solid-dose excipients. Public prescribing information identifies the product as a film-coated tablet containing telithromycin and standard tablet-processing materials.

The formulation architecture is expected to include:

• Lactose monohydrate as a diluent
• Microcrystalline cellulose as a filler and compression aid
• Povidone as a binder
• Croscarmellose sodium as a disintegrant
• Magnesium stearate as a lubricant
• Film-coating materials, including hypromellose or a comparable polymer
• Talc and titanium dioxide as coating components
• Colorants used to produce the tablet’s appearance

The exact qualitative and quantitative composition is controlled by the approved product dossier. Public labeling may identify inactive ingredients without disclosing every manufacturing parameter or the precise concentration of each component. Generic manufacturers therefore must demonstrate pharmaceutical equivalence and bioequivalence rather than simply reproduce the branded formulation by ingredient name.

Excipient functions in the KETEK formulation

Excipient category	Likely function	Commercial relevance
Lactose monohydrate	Dilution and tablet mass	Low-cost, widely available
Microcrystalline cellulose	Compression and mechanical strength	Supports direct compression or dry granulation
Povidone	Granulation binder	Can affect dissolution and tablet hardness
Croscarmellose sodium	Rapid disintegration	Important for immediate-release performance
Magnesium stearate	Lubrication	Excess use can slow dissolution
Film-coating polymer	Protection, swallowability, appearance	Supports product identification and stability
Titanium dioxide and pigments	Opacity and color	Subject to regional regulatory and customer preferences
Talc	Anti-tacking and coating performance	Relevant to coating process control

The principal excipient risk is not a novel delivery technology. It is control of dissolution, coating uniformity, tablet hardness, and stability while avoiding changes that could affect bioequivalence.

What excipient strategy is appropriate for a telithromycin generic?

A generic telithromycin developer should use a conservative immediate-release formulation strategy. The commercial objective is to match the reference product’s dissolution and pharmacokinetic profile with a supply chain that is less expensive and more resilient.

Preferred formulation approach

A practical strategy would use:

1. A lactose or lactose-cellulose filler system.
2. Croscarmellose sodium or another established superdisintegrant.
3. Povidone or a comparable binder.
4. Magnesium stearate at a controlled concentration and blending time.
5. A robust aqueous or organic film-coating process, subject to stability and solvent controls.
6. Excipient suppliers with multiple qualified manufacturing sites.

The formulation should minimize unnecessary excipient changes. Telithromycin is a low-dose active relative to total tablet mass, so content uniformity and powder segregation are important development risks. The developer should evaluate particle-size distribution, bulk density, flow, blend uniformity, and compression behavior.

Key technical development variables

Development variable	Potential impact
API particle size	Dissolution and blend uniformity
Lubricant concentration	Tablet ejection and dissolution rate
Disintegrant level	Disintegration time and release profile
Binder concentration	Hardness, friability, and dissolution
Coating weight gain	Appearance, moisture protection, and release
Lactose grade	Flow, compaction, and stability
Moisture exposure	Tablet strength and chemical stability
Packaging system	Shelf life and humidity protection

The formulation should be designed around discriminatory dissolution testing. A tablet that passes a single routine dissolution condition may still diverge from the reference product under pH, agitation, or storage conditions that expose formulation differences.

What commercial opportunities exist for KETEK excipients?

The strongest opportunity is component substitution rather than a proprietary excipient platform.

1. Generic excipient supply

Excipient manufacturers can target suppliers of telithromycin tablets with:

• Direct-compression lactose grades
• Co-processed lactose-cellulose systems
• High-functionality microcrystalline cellulose
• Low-viscosity povidone grades
• Fast-disintegrating croscarmellose sodium
• Ready-to-use film-coating systems
• Magnesium stearate with controlled surface area and particle size

These products can reduce manufacturing variability and simplify technology transfer. The opportunity is modest because telithromycin volumes are limited and the excipients are largely commoditized.

2. Supply-chain replacement

A manufacturer may seek a second source when the original excipient supplier has:

• Long lead times
• Site-concentration risk
• Regional registration limitations
• Inconsistent particle-size specifications
• Pricing pressure
• Updated regulatory documentation requirements

A qualified alternate source can create value without changing the formulation’s functional profile. The principal evidence package would include comparative material characterization, process compatibility, dissolution data, stability, and change-control documentation.

3. Film-coating systems

A ready-to-use coating system may offer the most practical value. It can improve color consistency, reduce coating development time, and support regional product differentiation. The coating must preserve tablet identification without creating a dissolution or stability difference.

Coating suppliers may also offer titanium-dioxide-free systems for jurisdictions or customers seeking alternative pigments. That change would require evaluation of opacity, color matching, light protection, process performance, and regulatory acceptability.

4. Contract manufacturing support

Contract manufacturers with validated immediate-release tablet platforms may be able to produce telithromycin using existing equipment. The commercial case depends on minimum batch size, API cost, market authorization, and the availability of an active buyer. Excipients are unlikely to be the primary margin driver.

What formulation patents protect KETEK?

The original KETEK product was supported by composition, pharmaceutical formulation, and manufacturing patents associated with telithromycin and ketolide chemistry. The commercial relevance of those patents is now limited by age and expiration.

Patent protection for an early-2000s small-molecule antibiotic would ordinarily have a 20-year term measured from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, and any applicable patent-term extension. Any core telithromycin composition patents would therefore be expected to have expired or be near expiration by 2024-2026.

Publicly available regulatory materials do not establish a commercially meaningful, unexpired U.S. formulation patent blocking a conventional telithromycin tablet. A current freedom-to-operate review would still need to assess jurisdiction-specific patents, continuations, manufacturing claims, and any later patents covering crystalline forms, impurities, or specific processes.

Patent-strength assessment

Patent category	Current commercial importance
Core telithromycin composition	Low; original protection is aged
Tablet formulation	Low to moderate, depending on jurisdiction and claim scope
Manufacturing process	Potentially relevant for specific routes or intermediates
Crystalline form	Requires jurisdiction-specific review
Method of use	Limited by product safety and market contraction
Excipient combination	Usually weak unless tied to a narrow, non-obvious performance result
New delivery system	Potentially patentable but commercially unproven

An excipient patent would need more than a routine combination of lactose, cellulose, binder, disintegrant, lubricant, and coating polymer. Patentable value would be stronger where the formulation demonstrates an unexpected dissolution, stability, impurity-control, or bioavailability result.

When does KETEK lose exclusivity and what is the generic-entry risk?

KETEK’s meaningful U.S. exclusivity has already ended. The major commercial barriers are no longer basic small-molecule patent exclusivity. They are safety perception, limited demand, regulatory requirements, and the cost of maintaining a low-volume antibiotic product.

The generic-entry scenario is therefore different from a high-revenue branded medicine:

• A generic applicant could face limited patent risk if no enforceable blocking patent remains.
• Paragraph IV litigation risk appears commercially modest unless a later patent is listed or asserted.
• The main regulatory burden is demonstrating pharmaceutical equivalence, bioequivalence, manufacturing quality, and adequate labeling.
• A generic launch could be unattractive if physicians avoid telithromycin because of hepatic safety concerns.
• Hospital and pharmacy demand may be insufficient to support multiple manufacturers.

The Orange Book should be checked for current active listings, reference-product status, patent entries, and exclusivity codes. Historical listings alone do not establish a current barrier to approval or launch. The FDA’s Orange Book is the controlling public source for listed patents and exclusivity information in the United States (FDA, 2024).

What is the Paragraph IV and litigation outlook for KETEK?

The Paragraph IV opportunity is limited. A conventional telithromycin generic could challenge any remaining listed patent by certifying that the patent is invalid, unenforceable, or not infringed. The commercial value of a Paragraph IV filing depends on whether the reference product has enough market value to justify litigation.

The principal risks are:

• A listed formulation or method-of-use patent that remains enforceable.
• A patent covering a specific polymorph or manufacturing route.
• Unclear reference-product or discontinued-product status.
• FDA questions concerning bioequivalence to a discontinued or difficult-to-source reference product.
• Product-liability exposure associated with a drug carrying a serious liver-injury history.

No major current U.S. litigation campaign is evident from the publicly established history of KETEK. A definitive litigation conclusion requires a current review of the Orange Book, FDA approval records, USPTO patent status, and federal court dockets.

How does KETEK compare with competing antibiotics?

Telithromycin has a weaker commercial position than established respiratory antibiotics because its safety profile reduces prescribing flexibility.

Product class	Commercial comparison with KETEK
Azithromycin and clarithromycin	Larger historical prescribing base and stronger generic supply
Amoxicillin/clavulanate	Broader routine use and established low-cost manufacturing
Respiratory fluoroquinolones	Competing efficacy in selected indications, although their own safety limitations apply
Newer branded antibiotics	Higher price potential but stronger patent and clinical differentiation
Other ketolides	Limited market penetration and similar class-level constraints

KETEK’s formulation is technically straightforward. Its competitive weakness is clinical and commercial rather than excipient-related.

What are the main manufacturing and IP barriers?

The most important manufacturing barriers are API availability, impurity control, content uniformity, dissolution matching, and low production scale. A developer must also manage:

• Qualified telithromycin API sources
• Genotoxic or process-related impurity assessment
• Residual solvents and elemental impurities
• Stability under heat and humidity
• Packaging suitable for a film-coated tablet
• Validation of cleaning procedures for potent antibiotic residues
• Consistent tablet appearance and identification

Manufacturing IP could matter if the API source relies on a protected synthetic route. A finished-dose manufacturer can reduce exposure by using a different process, sourcing from a licensed supplier, or relying on an expired route patent. This issue is separate from excipient strategy.

What commercial opportunities remain?

The realistic opportunities are niche and operational:

1. Regional generic supply: Markets where telithromycin remains authorized and has residual demand.
2. Second-source excipients: Substitution of lactose, cellulose, binder, disintegrant, lubricant, or coating suppliers.
3. Contract manufacturing: Small-batch production for regional license holders.
4. Regulatory maintenance: Support for post-approval excipient changes and site transfers.
5. Analytical services: Comparative dissolution, impurity profiling, stability, and bioequivalence support.
6. Specialized packaging: Moisture-protective packaging and serialized supply for controlled regional distribution.

A new pediatric, liquid, modified-release, or taste-masked product would require a stronger clinical and regulatory rationale. Telithromycin’s safety profile makes investment in a new delivery system difficult to justify absent a demonstrated reduction in systemic or hepatic risk.

Key Takeaways

• KETEK contains telithromycin in a conventional immediate-release film-coated tablet.
• Its excipient system is based on standard diluents, binders, disintegrants, lubricants, and coating materials.
• The best excipient opportunity is generic manufacturing support and qualified supplier substitution.
• Core patent and exclusivity barriers are likely aged or expired, but current Orange Book and jurisdiction-specific reviews remain decisive.
• Paragraph IV litigation risk is likely limited by the product’s small commercial market.
• Severe hepatotoxicity concerns and discontinued U.S. marketing reduce demand more than excipient or formulation barriers.
• New dosage-form development has weak commercial prospects unless it addresses a specific safety or regulatory objective.
• Revenue potential is regional and supply-chain driven, not comparable with active branded antibiotics.

FAQs

Can lactose-free excipients improve the commercial position of KETEK?

Possibly, but the benefit is limited. A lactose-free formulation could address patient or customer preferences, but it would require comparative dissolution, stability, and bioequivalence assessment. It would not resolve telithromycin’s principal commercial barrier, which is safety perception.

Is a liquid telithromycin formulation commercially attractive?

The opportunity is weak. A liquid formulation would require new stability, preservative, taste, dosing, packaging, and pediatric-use data. The hepatic safety history makes pediatric expansion particularly difficult.

Could a co-processed excipient reduce KETEK manufacturing cost?

Yes, a co-processed filler-binder or direct-compression system could reduce granulation steps and improve flow. The economic value depends on batch scale and whether the new excipient preserves bioequivalence and dissolution.

Are KETEK excipients likely to create a patent barrier?

Usually not. Standard excipients are generally difficult to protect broadly. A defensible patent would need a narrow formulation claim supported by unexpected performance, such as improved stability, impurity control, or dissolution.

Does KETEK have biosimilar competition?

No. Telithromycin is a chemically synthesized small molecule, not a biologic. Any follow-on product would be regulated as a generic or another small-molecule equivalent, not a biosimilar.

References

1. European Medicines Agency. (2007). Questions and answers on the review of Ketek and other medicines containing telithromycin. EMA.

2. Food and Drug Administration. (2006). FDA public health advisory: Ketek (telithromycin). U.S. Department of Health and Human Services.

3. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. Food and Drug Administration. (2009). KETEK (telithromycin) prescribing information. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2007). FDA announces strengthened warnings for Ketek. U.S. Department of Health and Human Services.